Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., incorporated on November 20, 2006, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists primarily of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks.
The Company's products are sold throughout the United States and internationally. The Company's products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. The Company has its manufacturing operations in the United States and Latin America.
1129 N Mcdowell Blvd
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 1999.| Ticker | SNOA |
| Long Name | Sonoma Pharmaceuticals, Inc. |
| Short Name | Sonoma Pharma |